Form 4 for MLYS Mineralys Therapeutics, Inc.
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-17 · accession 0001672659-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-17 | MLYS | Rodman David Malcom | Chief Medical Off | S - Sale+OE | $27.59 | -417 | 44.1K | -0.9% | -$11.5K |
| D | 2026-02-17 | 2026-02-17 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $15.44 | +417 | 44.5K | +0.9% | +$6,438 |
| D | 2026-02-17 | 2026-02-17 | MLYS | Rodman David Malcom | Chief Medical Off | M - OptEx | $0.00 | -417 | 5,417 | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | S | D | 417 | $27.59 | 44,089 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-17 | M | A | 417 | $15.44 | 44,506 | D | — | — | |
| 3 | Derivative | Stock Option | 2026-02-17 | M | D | 417 | $0.00 | 5,417 | D | $15.44 · — to 2033-03-17 | 417 Common Stock | (F2) The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. |